Archive for the ‘Commentary’ Category

The long slog of medical R&D and finding inspiration

Author: Elizabeth Csaszar, 03/27/17

Research and development (R&D) of a medical therapeutic is a long slog. This isn’t news to anyone working in the field. The average time to bring a new drug product to market is over a decade. Moreover, this is the timeline when everything progresses well – funding and business decisions align, manufacturing processes come together,…Read more

Right Turn: Synthetic biology predicted to become a huge industry

Author: Stacey Johnson, 02/10/17

There is a trend in the regenerative medicine field to include gene therapies when describing the work being performed by academics and industry, as in “cell and gene therapies.” The wider definition better reflects how the industry is evolving and acknowledges the dual focus. I expect the same may happen with synthetic biology’s role in…Read more

Peter Zandstra and CCRM: Making cell therapies a commercial reality

Author: Guest, 01/31/17

Dr. Rohin Iyer is currently a Development Manager at GE Healthcare / CCRM. He did his PhD in Biomedical Engineering at the University of Toronto, and has been working in the field of stem cells and tissue engineering for over 12 years. He is an avid tweeter (follow @DrRohinIyer) on cell therapies and regenerative medicine. …Read more

Right Turn: W.O.M.E.N. in Advanced Therapies welcoming members

Author: Stacey Johnson, 01/20/17

A special thing happened this week at Phacilitate’s Cell and Gene Therapy World: W.O.M.E.N. in Advanced Therapies launched. The virtual group is the result of conversations begun more than a year ago with like-minded individuals who want to give women the tools they need to succeed in an industry – like many – where there…Read more

Making a case for research investment in Canada: Can we drive reverse brain drain now?

Author: Camila Londono, 01/11/17

Brain drain was a real problem for Canada in the late ‘90s. A study by Statistics Canada found that twice as many post-secondary professors and teachers went to the United States than came to Canada in that period. This untenable situation—in which education and infrastructure investments in people were lost through decreased funding, higher taxes…Read more

Inaugural Medicine by Design Symposium – Engineering progress in regenerative medicine

Author: Nicole Forgione, 12/21/16

On November 28 local and international leaders of the regenerative medicine (RM) community gathered at the MaRS Centre in Toronto for the first ever Medicine by Design (MbD) Symposium. The event marked the first year of the MbD program at the University of Toronto (U of T). This initiative was established based on a $114…Read more

Right Turn: Every damn swan – a note on the scientific hypothesis

Author: Guest, 12/02/16

Malgosia Pakulska is a research associate in the Shoichet lab at the University of Toronto and a science writer for Research2Reality, a blog designed to engage the public in Canadian research. Malgosia wants to educate, entertain, and show people what science is really like, one story at a time. When she is not in the lab,…Read more

Insights from CGTW16 – Part 3: Clinical trials, health economics and regulatory affairs

Author: Guest, 12/01/16

Amin Adibi is a biomedical engineer and a research assistant at the University of British Columbia. His areas of interest include cell manufacturing and bioprocess optimization, clinical translation of cellular therapies, health outcomes and cost-effectiveness modelling. Amin has an MSc degree from University of Calgary, where he focused on developing adjuvant MSC-based therapies for brain…Read more

Insights from CGTW16 – Part 2: scale-up challenges and closed systems

Author: Guest, 11/23/16

Amin Adibi is a biomedical engineer and a research assistant at the University of British Columbia. His areas of interest include cell manufacturing and bioprocess optimization, clinical translation of cellular therapies, health outcomes and cost-effectiveness modelling. Amin has an MSc degree from University of Calgary, where he focused on developing adjuvant MSC-based therapies for brain…Read more

Right Turn: What do the results of the U.S. election mean for science?

Author: Stacey Johnson, 11/09/16

This isn’t the blog that I planned to write this week, but I’m so preoccupied with the outcome of the U.S. election, I’m finding it hard to focus on anything else right now. So, let’s look at the implications of a Trump presidency on science. An article in Nature quotes Michael Lubell, director of public…Read more